Abingworth Company Growth Through Strategic Acquisitions

Abingworth's strategic approach to company growth has been a key factor in its success. The firm has made several significant acquisitions over the years.

Abingworth has a long history of identifying and investing in promising companies, often at an early stage of development. This approach has allowed the firm to build a diverse portfolio of investments.

One notable example is the firm's investment in a biotechnology company, which has since become a leading player in its field. Abingworth's support and guidance played a crucial role in the company's growth and success.

Through its strategic acquisitions and investments, Abingworth has established itself as a major player in the venture capital industry.

Consider reading: Responsability Investments

Abingworth had less than 10 employees as of 2001, but the company managed a significant $300 million across several funds.

The firm's growth was impressive, with one of its funds reaching a managed value of $375 million by 2014.

Abingworth had two managing partners, Timothy J. Haines and Kurt von Emster, as of 2016.

The company has a board of directors, which consisted of two members in 2016, Stephen Bunting and Theodore Clark.

David Leathers, a "special partner", joined the firm in 1987, having left Rothschild.

James Abell has held the post of chief financial officer since at least 2001.

By 2014, the company had established ten life science investment funds, with Stephen Bunting involved in the establishment of each of them.

Abingworth raised $356 million to invest in late-stage drug development, extending its "co-development" strategy.

The company's newest fund will finance broader study of medicines far along in testing or already on market.

For another approach, see: Malaysia Development Bank

Abingworth is a venture capital firm with a rich history. The company was established in 1973.

As of 2001, Abingworth had a relatively small team, with less than 10 employees. By 2016, the firm had grown to over 20 employees.

One of the key figures at Abingworth is David Leathers, who joined the firm in 1987 as a "special partner" after leaving Rothschild. James Abell has been the company's chief financial officer since at least 2001.

Abingworth's leadership team has included several experienced professionals. As of 2016, the firm had two managing partners, Timothy J. Haines and Kurt von Emster.

The company's board of directors has consisted of experienced individuals. In 2016, the board consisted of two members, Stephen Bunting and Theodore Clark.

Here are the key dates in Abingworth's history:

Abingworth made a significant move in August 2022, as it was acquired by The Carlyle Group.

The acquisition brought a substantial amount of assets under management, with Abingworth having approximately $2 billion in assets at the time of the deal.

Broaden your view: Apax Partners Assets under Management

Abingworth's latest fund is a game-changer for late-stage drug development, with a whopping $582 million co-development fund at its disposal.

This massive investment will enable the firm to take a more comprehensive approach to testing medicines that are already in advanced stages of development.

The firm's co-development strategy involves financing broader studies of these medicines, which can be a major advantage in getting them to market.

Abingworth's expertise in this area is evident in its ability to raise significant funds for late-stage trials.

The firm's newest fund extends its co-development strategy, allowing it to invest in even more medicines that are far along in testing or already on the market.

Broaden your view: Ellicott Development Co.

In August 2022, Abingworth was acquired by The Carlyle Group.

The acquisition added significant assets to The Carlyle Group's portfolio.

Abingworth had approximately $2 billion in assets under management at the time of the acquisition.

Discover more: Acquisition of Twitter by Elon Musk

Abingworth's investment strategy has evolved over the years, with a focus on establishing funds with specific targets. The firm's investment approach involves exits, which can be through acquisitions or initial public offerings.

In the late 1980s, Abingworth created its biotech investment arm and made its first investment in Immunology Ltd, later renamed Cantab Pharmaceuticals. This marked a significant shift in the company's investment focus.

The firm's early biotech investments, such as Dicerna Pharmaceuticals and Clovis Oncology, saw initial public offerings in the early 2000s. Abingworth also provided funding for Oxagen in 2000, supporting the company's growth.

The firm's ability to exit investments successfully has been demonstrated through its acquisition of Algeta by Bayer in 2009. This was the firm's first venture investment in public equities, marking a significant milestone.

Readers also liked: Caledonia Investments

Abingworth's investment in Syntaxin Ltd resulted in a successful exit in 2013, when the company was acquired by Ipsen SA. The firm also invested in Effector Therapeutics in 2013, further expanding its portfolio.

The company's investment in Avedro and Gensight Biologics in 2014 highlights its ongoing commitment to supporting innovative companies.